RxDoctor Payments Data

James Weaver, MD

Internal Medicine · Asheville, NCNPI 1083608210

Payments from drug & device makers

$200in general payments, 2019–2025

Across 6 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$107
  • Novo Nordisk$44
  • Boehringer Ingelheim$20
  • Pfizer$15
  • Amgen$15

What the payments were for

  • Food & beverage$200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson2$107
Novo Nordisk1$44
Boehringer Ingelheim1$20
Pfizer1$15
Amgen1$15

How this compares

$200 in reported general payments places this provider in the 50th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$350,777
Medicare patients
530
Services billed
9,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$189,933
JardianceEmpagliflozin152$133,062
XareltoRivaroxaban109$120,551
OzempicSemaglutide79$97,658
JanuviaSitagliptin Phosphate51$57,500
MounjaroTirzepatide36$55,369
TrulicityDulaglutide33$39,932
Repatha SureclickEvolocumab33$23,883
ShingrixVaricella-Zoster Ge/As01b/Pf81$18,271
InvokanaCanagliflozin19$17,603
ArexvyRsvpref3 Antigen/As01e/Pf54$16,948
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,548
Valsartan248$8,607
Breo ElliptaFluticasone/Vilanterol13$8,414
Rosuvastatin Calcium541$7,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$189,933193 claims
Johnson & JohnsonXarelto, Invokana$107$138,154128 claims
Boehringer IngelheimJardiance$20$133,062152 claims
Novo NordiskOzempic$44$97,65879 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →